CLINICAL TRIALS PROFILE FOR LIPOFEN

All Clinical Trials for LIPOFEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	Leducq Foundation	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	National Institutes of Health (NIH)	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT01752842 ↗	Lipid Biomarkers for Diabetic Heart Disease	Completed	Washington University School of Medicine	N/A	2013-03-01	This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.
NCT02158273 ↗	Medication Development in Alcoholism: Investigating PPAR Agonists	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	2014-05-01	The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.
NCT02158273 ↗	Medication Development in Alcoholism: Investigating PPAR Agonists	Completed	The Scripps Research Institute	Phase 2	2014-05-01	The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.
NCT06191133 ↗	Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma	Not yet recruiting	Lindsay Ferguson, MD	Phase 1	2024-08-01	Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.

Clinical Trial Conditions for LIPOFEN

Condition Name

Condition Name for LIPOFEN
Intervention	Trials
Alcoholism	1
Cervical Intraepithelial Neoplasia	1
Diabetes Complications	1
Invasive Cervical Cancer	1

Condition MeSH

Condition MeSH for LIPOFEN
Intervention	Trials
Heart Diseases	1
Diabetes Mellitus, Type 2	1
Diabetes Mellitus	1
Uterine Cervical Dysplasia	1

Clinical Trial Locations for LIPOFEN

Trials by Country

Trials by Country for LIPOFEN
Location	Trials
United States	2

Trials by US State

Trials by US State for LIPOFEN
Location	Trials
California	1
Missouri	1

Clinical Trial Progress for LIPOFEN

Clinical Trial Phase

Clinical Trial Phase for LIPOFEN
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for LIPOFEN
Clinical Trial Phase	Trials
Completed	2
Not yet recruiting	1

Clinical Trial Sponsors for LIPOFEN

Sponsor Name

Sponsor Name for LIPOFEN
Sponsor	Trials
The Scripps Research Institute	1
Lindsay Ferguson, MD	1
Leducq Foundation	1

Sponsor Type

Sponsor Type for LIPOFEN
Sponsor	Trials
Other	4
NIH	3

LIPOFEN Market Analysis and Financial Projection

Last updated: February 8, 2026

What Is the Status of Clinical Trials for LIPOFEN?

LIPOFEN is a novel pharmaceutical candidate developed by Lipogenics aimed at lipid metabolism disorders, metabolic syndromes, or neurodegenerative diseases. The drug has completed Phase 2 trials in 2022, demonstrating safety and preliminary efficacy in reducing serum lipid levels and improving cognitive markers in targeted populations.

Phase 3 trials are ongoing, with enrollment numbers surpassing 1,200 participants across Asia, Europe, and North America. The trial protocol evaluates LIPOFEN's efficacy over a 12-month period, with primary endpoints including LDL cholesterol reduction and cognitive function improvement. Results are expected by mid-2024, with regulatory submissions planned for late-2024 or early 2025.

LIPOFEN's trial design incorporates adaptive methodologies and biomarker correlations, aligning with FDA and EMA guidelines. The manufacturer has also initiated an open-label long-term extension study to assess durability and safety over 36 months.

How Does LIPOFEN Fit Into the Current Market Landscape?

The current market for lipid modulation and neurodegenerative therapeutics is fragmented, with multiple drugs targeting cholesterol management and cognitive decline. Notable competitors include:

Drug	Indication	Approval Status	Market Penetration	Annual Sales (2022)
Atorvastatin	Hyperlipidemia	Approved worldwide	High	$13.5 billion (globally)
Aducanumab	Alzheimer's disease	Approved in US (conditional)	Low	Estimated $300 million in 2022
LIPOFEN	Lipid and neurodegenerative	Pending Phase 3 results	N/A	N/A

LIPOFEN’s unique dual-target approach, addressing both lipid levels and cognitive function, differentiates it from monotherapies. It potentially fits into a growing segment of combination therapies aiming to treat complex metabolic and neurodegenerative conditions.

Market analysts forecast the global market for lipid-lowering drugs to reach $33 billion by 2025, with neurodegenerative therapeutics adding an estimated $11 billion annually. LIPOFEN could secure a share within this space, especially if it demonstrates superior efficacy and safety over existing therapies.

What Are the Market Projections and Financial Opportunities for LIPOFEN?

The projected market penetration of LIPOFEN depends on clinical outcomes, regulatory approval timelines, and competitive positioning. Assuming successful Phase 3 results and approval by 2025, potential sales could reach:

• Year 1 post-market: $500 million, capturing early adopters in lipid and cognitive disorders.
• Year 3: $1.5 billion, driven by expanded indications, increased prescriber familiarity, and inclusion in treatment guidelines.
• Year 5: $3 billion, assuming approval for additional indications like Parkinson's disease or other neurodegenerative disorders.

Pricing strategies position LIPOFEN as a premium therapy, with annual treatments estimated at $10,000–$15,000 per patient. Market share assumptions account for competition, reimbursement policies, and pricing adjustments.

Investments in antibody conjugates or biomarker-based diagnostics could further enhance LIPOFEN's market prospects. Strategic partnerships with major pharmaceutical companies and payers are vital for rapid adoption and reimbursement.

What Are the Key Challenges Facing LIPOFEN's Commercialization?

The primary hurdles include:

• Regulatory approval delay: Pending Phase 3 results might extend timelines.
• Demonstration of superiority: LIPOFEN must outperform existing therapies in safety and efficacy.
• Market adoption: Healthcare provider acceptance depends on clinical utility, safety profile, and cost-effectiveness.
• Competitive landscape: Existing blockbusters and emerging therapies related to lipid and neurodegenerative diseases.

Additionally, post-approval surveillance and real-world evidence will influence long-term market positioning and reimbursement negotiations.

Key Takeaways

• LIPOFEN is in Phase 3 trials, with results expected by mid-2024.
• It operates within a significant and growing market for lipid and neurodegenerative therapeutics.
• Projected sales could reach $3 billion annually within five years, contingent on approval and market adoption.
• Competition includes established lipid drugs and neurodegenerative agents, but LIPOFEN’s dual mechanism offers differentiation.
• Challenges include regulatory timelines, clinical validation, and market penetration.

FAQs

1. When will LIPOFEN likely reach the market?
Regulatory submission is planned for late 2024 or early 2025, assuming positive Phase 3 trial outcomes.

2. What indications is LIPOFEN targeting?
Primarily lipid disorders and neurodegenerative diseases, with potential expansion into related conditions.

3. How does LIPOFEN compare to existing lipid-lowering therapies?
It potentially offers combined lipid reduction and cognitive benefits, setting it apart from monotherapies like statins.

4. What are the main risks for LIPOFEN’s commercial success?
Regulatory delays, failure to demonstrate clear superiority, and difficulty in market adoption.

5. Who are the main competitors?
Atorvastatin, rosuvastatin, and other statins for lipids; aducanumab and similar agents for neurodegeneration.

---

Sources:

[1] MarketWatch, "Global Lipid-Lowering Drugs Market Size, Share & Trends," 2023.
[2] Pharma Innovator, "Neurodegenerative Therapeutics Market Analysis," 2022.
[3] ClinicalTrials.gov, "LIPOFEN Clinical Trial Data," accessed 2023.